financetom
Business
financetom
/
Business
/
NCR Atleos Q2 Adjusted Earnings Fall, Revenue Rises; Updates 2024 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
NCR Atleos Q2 Adjusted Earnings Fall, Revenue Rises; Updates 2024 Outlook
Aug 13, 2024 1:57 PM

04:33 PM EDT, 08/13/2024 (MT Newswires) -- NCR Atleos ( NATL ) reported Q2 adjusted earnings late Tuesday of $0.81 per diluted share, down from $1.67 per share a year earlier.

Two analysts surveyed by Capital IQ expected $0.68.

Revenue for the quarter ended June 30 was $1.08 billion, up from $1.04 billion a year ago.

Two analysts polled by Capital IQ expected $1.08 billion.

The company expects Q3 non-GAAP EPS of $0.71 to $0.81 and revenue of $1.05 billion to $1.08 billion. Analysts surveyed by Capital IQ expect EPS of $0.90, on revenue of $1.08 billion.

The company expects 2024 non-GAAP EPS of $2.90 to $3.20 on revenue of $4.26 billion to $4.34 billion. It expected adjusted EPS of $2.90 to $3.20 on revenue of $4.20 billion to $4.40 billion previously. Analysts project EPS of $3.11 on revenue of $4.32 billion.

Price: 29.78, Change: +0.38, Percent Change: +1.29

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company
Mar 25, 2026
BEIJING, March 25, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ( LSBWF ) (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the Special Committee) has received a revised preliminary non-binding...
I Bella Perfect Files for Nasdaq IPO to Sell 3.75 Million Shares
I Bella Perfect Files for Nasdaq IPO to Sell 3.75 Million Shares
Mar 25, 2026
07:31 AM EDT, 03/25/2026 (MT Newswires) -- I Bella Perfect (IBP) said Wednesday that it has filed to sell 3.75 million Class A shares in an initial public offering at an expected price range of $4 to $6 per share, according to an amended Form F-1 filed with the US Securities and Exchange Commission. The Malaysian aesthetic medical clinics operator...
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
Mar 25, 2026
Board to evaluate a range of alternatives while continuing to support core business priorities ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. ( NDRA ) , a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that its Board of Directors has initiated a process to evaluate a range of strategic...
Biogen Reportedly Signs Licensing Deal With South Korea's Alteogen
Biogen Reportedly Signs Licensing Deal With South Korea's Alteogen
Mar 25, 2026
07:32 AM EDT, 03/25/2026 (MT Newswires) -- Biogen (BIIB) has signed a licensing deal with South Korea's Alteogen for subcutaneous biopharmaceutical formulations based on the ALT-B4 platform, a technology that converts intravenous drugs into subcutaneous injections, news outlets reported Wednesday, citing Alteogen. Under the agreement, Biogen secures exclusive rights to develop and commercialize two biopharmaceutical products using Alteogen's ALT-B4 platform...
Copyright 2023-2026 - www.financetom.com All Rights Reserved